Page 93 - Read Online

Page 10 of 12 Loria et al. Hepatoma Res 2018;4:59 I http://dx.doi.org/10.20517/2394-5079.2018.75

malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991;178:493-7.
20. Ng IO. Prognostic significance of pathological and biological factors in hepatocellular carcinoma. J Gastroenterol Hepatol 1998;13:666-70.
21. Nicolau C, Catalá V, Vilana R, Gilabert R, Bianchi L, Solé M, Pagés M, Brú C. Evaluation of hepatocellular using SonoVue, a second
generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 2004;14:1092-9.
22. Serra C, Righi S, Molo CD, Felicani C. Current role of contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol
Gastroint Dis 2015;1:102.
23. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen
MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu
F, Solbiati L, Weskott HP, Xu HX; World Federation for Ultrasound in Medicine; European Federation of Societies for Ultrasound.
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012. A
WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol
2013;39:187-210.
24. Cosgrove D, Harvey C. Clinical uses of microbubbles in diagnosis and treatment. Med Biol Eng Comput 2009;47:813-26.
25. Claudon M, Cosgrove D, Albrecht T, Bolondi L, Bosio M, Calliada F, Correas JM, Darge K, Dietrich C, D’Onofrio M, Evans DH, Filice C,
Greiner L, Jäger K, Jong Nd, Leen E, Lencioni R, Lindsell D, Martegani A, Meairs S, Nolsøe C, Piscaglia F, Ricci P, Seidel G, Skjoldbye
B, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T. Guidelines and good clinical practice recommendations for contrast
enhanced ultrasound (CEUS) - update 2008. Ultraschall Med 2008;29:28-44.
26. Simpson DH, Chin CT, Burns PN. Pulse inversion Doppler: a new method for detecting nonlinear echoes from microbubble contrast agents.
IEEE Trans on Ultrason, Ferroelectr, and Freq Control 1999;46:372-82..
27. Tiemann K, Lohmeier S, Kuntz S, Köster J, Pohl C, Burns P, R T, Nanda NC, Lüderitz B, Becher H. Real-time contrast echo assessment of
myocardial perfusion at low emission power: first experimental and clinical results using power pulse inversion imaging. Echocardiography
1999;16:799-809.
28. Averkiou M, Powers J, Skyba D, Bruce M, Jensen S. Ultrasound contrast imaging research. Ultrasound Q 2003;19:27-37.
29. Szabo T. Diagnostic ultrasound imaging. Amsterdam: Academic Press; 2004.
30. Dietrich CF, Ignee A, Hocke M, Schreiber-Dietrich D, Greis C. Pitfalls and artefacts using contrast enhanced ultrasound. Z Gastroenterol
2011;49:350-6.
31. Loria F, Loria G, Basile S, Crea G, Randazzo D, Frosina L. Contrast-enhanced ultrasound of hepatocellular carcinoma: correlation between
enhancement pattern and cellular differentiation on histopathlogy. Updates Surg 2012;64:247-55.
32. Murakami T, Tsurusaki M, Hyodo T, Imai Y. Clinical utility of imaging for evaluation of hepatocellular carcinoma. J Hepatocell Carcinoma
2014;1:101-8.
33. Gaiani S, Volpe L, Piscaglia F, Bolondi L. Vascularity of liver tumours and recent advances in doppler ultrasound. J Hepatol 2001;34:474-
82.
34. Xu HX, Liu GJ, Lu MD, Xie XY, Xu ZF, Zheng YL, Liang JY. Characterization of small focal liver lesions using real-time contrast-enhanced
sonography: diagnostic performance analysis in 200 patients. J Ultrasound Med 2006;25:349-61.
35. Xu HX, Liu GJ, Lu MD, Xie XY, Xu ZF, Zheng YL, Liang JY. Characterization of focal liver lesions using contrast-enhanced sonography
with a low mechanical index mode and a sulfur hexafluoride-filled microbubble contrast agent. J Clin Ultrasound 2006;34:261-72.
36. Xu HX, Xie XY, Lu MD, Liu GJ, Xu ZF, Zheng YL, Liang JY, Chen LD. Contrast-enhanced sonography in the diagnosis of small
hepatocellular carcinoma < or =2 cm. J Clin Ultrasound 2008;36:257-66.
37. Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L, Pozzi-Mucelli R. Characterization of focal liver lesions with contrast-specific
US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004;232:420-30.
38. Zheng SG, Xu HX, Liu LN. Management of hepatocellular carcinoma: the role of contrast-enhanced ultrasound. World J Radiol 2014;6:7-
14.
39. Gaiani S, Celli N, Piscaglia F, Cecilioni L, Losinno F, Giangregorio F, Mancini M, Pini P, Fornari F, Bolondi L. Usefulness of contrast-
enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol
2004;41:421-6.
40. Chen MH, Dai Y, Yan K, Fan ZH, Yin SS, Yang W, Wu W, Wang YB, Li JY. The role of contrast-enhanced ultrasound on the diagnosis of
small hepatocellular carcinoma (</=3cm) in patients with cirrhosis. Hepatol Res 2006;35:281-8.
41. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, Della Corte C, Ronchi G, Rumi MG, Biondetti
P, Colombo M. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in
cirrhosis. Gut 2010;59:638-44.
42. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, Bolondi L. The impact of vascular and nonvascular findings on the noninvasive
diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010;105:599-609.
43. International Agency for Research Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.
Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. [Last accessed on 14 Sep 2018]
44. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
45. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of
compensated cirrhosis due to hepatitis C virus: a 17- year cohort study of 214 patients. Hepatology 2006;43:1303-10.
46. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with
cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-45.
47. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma
development: a meta-analysis. J Hepatol 2009;50:1142-54.
48. European Association for the Study of the Liver. European organisation for research and treatment of cancer. EASL-EORTC clinical
practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.